ABSOLUTE QUANTITATION IN NEUROLOGICAL PET - DO WE NEED IT

被引:9
|
作者
STROTHER, SC
LIOW, JS
MOELLER, JR
SIDTIS, JJ
DHAWAN, VJ
ROTTENBERG, DA
机构
[1] MEM SLOAN KETTERING CANC CTR,DEPT NEUROL,NEW YORK,NY 10021
[2] CORNELL UNIV,MED CTR,COLL MED,NEW YORK,NY 10021
来源
关键词
POSITRON EMISSION TOMOGRAPHY; ACQUIRED IMMUNE DEFICIENCY SYNDROME DEMENTIA COMPLEX; ABSOLUTE QUANTITATION; REGIONAL COVARIATION;
D O I
10.1038/jcbfm.1991.31
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This article addresses the question posed in the title by examining the effects of parameters traditionally associated with improved absolute quantitation, on the analysis of 12 acquired immune deficiency syndrome dementia complex (ADC) patients compared to a normal control group. Results are discussed within the framework of the subprofile scaling model (SSM) for analyzing patterns of regional covariation. It is demonstrated that the ability to extract measures of group discrimination and disease progression are unaffected by (1) limited improvements in image resolution, (2) the use of transmission scan smoothing, (3) the application of a scatter deconvolution correction, and (4) converting region-of-interest measurements of counts per voxel to measurements of regional CMR(glc). This "robustness" of the SSM approach is partly due to the extraction of disease-related subject weights, independent of any subject's global scaling effects. It is argued that other analysis techniques that initially reduce intersubject variation (e.g., using regional ratios or normalizing by global metabolic rates before applying traditional multivariate procedures) lack analytic features that may be important to identify multidimensional, disease-related image patterns. Based on the ADC patient data, it is concluded that measures of group discrimination and disease progression will not necessarily benefit from the optimization of parameters traditionally associated with improved absolute quantitation.
引用
收藏
页码:A3 / A16
页数:14
相关论文
共 50 条
  • [1] Do We Need PET?
    Schelbert, Heinrich R.
    [J]. JOURNAL OF NUCLEAR CARDIOLOGY, 2014, 21 (03) : 411 - 412
  • [2] Do We Need PET?
    Heinrich R. Schelbert
    [J]. Journal of Nuclear Cardiology, 2014, 21 : 411 - 412
  • [3] Quantification in PET: What is it? Can we do it? Do we need it?
    Marsden, PK
    [J]. NUCLEAR MEDICINE COMMUNICATIONS, 2004, 25 (07) : 635 - 636
  • [4] Do we need PET quality circles?
    Bokisch, A
    [J]. NUKLEARMEDIZIN, 1998, 37 (06) : A3 - A3
  • [5] Quantitation of NAD plus : Why do we need to measure it?
    Liu, Yue
    Clement, James
    Grant, Ross
    Sachdev, Perminder
    Braidy, Nady
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2018, 1862 (12): : 2527 - 2532
  • [6] How Many PET Tracers Do We Need?
    Schwaiger, Markus
    Wester, Hans-Juergen
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2011, 52 : 36S - 41S
  • [7] Bilirubin and neurological dysfunction - Do we need to change what we are doing?
    Maisels, MJ
    Newman, TB
    [J]. PEDIATRIC RESEARCH, 2001, 50 (06) : 677 - 678
  • [8] Do we need acute neurological services in A&E?
    Heaney, DC
    Campbell, N
    Cockerell, OC
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2003, 74 (08): : 1182 - 1182
  • [9] Neurological exotropia: do we need to decrease surgical dosing?
    Bang, Genie M.
    Brodsky, Michael C.
    [J]. BRITISH JOURNAL OF OPHTHALMOLOGY, 2013, 97 (02)
  • [10] LABELLING METHODS IN (PET-)RADIOPHARMACY: DO WE NEED ALTERNATIVES?
    Steinbach, Joerg
    [J]. JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2009, 52 (7-8): : 257 - 257